Treatments and Adherence to Treatment protocols

The European Partnership on One Health Antimicrobial Resistance (EUP OHAMR) is launching a Joint Transnational Call for research and innovation projects aimed at addressing the critical challenge of antimicrobial resistance (AMR). The call is part of the Horizon Europe funding program and will open on November 18, 2025. A total funding pool of €31,000,000 is available, with two cut-off deadlines on February 2, 2026, and June 17, 2026. Projects can last for a maximum duration of three years.

This initiative encourages transnational collaboration, requiring applicants to form comprehensive consortia involving multiple partners from at least two different countries. Eligible applicants include research funding organizations, academia, industry representatives including small and medium enterprises (SMEs), healthcare providers, and other relevant stakeholders. The call specifically targets three research areas:

1. Development of new combination therapies aimed at overcoming resistance to existing or innovative antimicrobials applicable in human, animal, and plant health.
2. Creation of tools and methods to enhance adherence to treatment protocols among end-users, addressing issues such as low compliance in humans, animals, and agriculture.
3. Assessment of the impact of veterinary and agricultural antimicrobial use on the transmission risk of AMR to humans and the environment, informing policy on restrictions of certain antimicrobials for human use.

The application process consists of two formal stages: a pre-proposal submission followed by an invitation for successful consortia to submit a full proposal. Submissions must be made electronically through the EUP OHAMR online platform. The evaluation will focus on several criteria, including scientific excellence, impact, and implementation quality, each weighted equally. Additionally, the proposals undergo a formal check and independent peer review.

Furthermore, while the document does not specify universal co-funding requirements, it suggests that individual national or regional funding organizations might impose their regulations, potentially requiring matching funds or in-kind contributions.

Notably, the expected success rate of submissions is competitive, continuing the robust examination commonly found in Horizon Europe calls, with historical rates typically ranging from 10% to 39%. Applicants are encouraged to review the specific eligibility and participation guidelines on the EUP OHAMR website to ensure compliance.

Overall, this call represents a substantial investment in combating antimicrobial resistance, promoting innovative and collaborative solutions across various sectors, including healthcare, agriculture, and environmental management. Successful projects will be pivotal in generating evidence-based strategies and tools critical to informing effective policies and practices combatting AMR.

The European Partnership on One Health AntiMicrobial Resistance (EUP OHAMR) 2026 Joint Transnational Call is a Horizon Europe funding programme initiative aimed at supporting Research and Innovation (R&I) to address the challenges of Antimicrobial Resistance (AMR). The call opened on 18 November 2025. There are multiple cut-off deadlines, the first being 02 February 2026 at 13:00 (Brussels time) and the second being 17 June 2026 at 13:00 (Brussels time). The maximum project duration is three years, with a total funding of 31,000,000.00 EUR available. The project acronym is OHAMR, and the grant agreement number is 101217154. The topic is HORIZON-HLTH-2024-DISEASE-09-01 European Partnership: One Health Anti-Microbial Resistance.

The call addresses three main topics:

Topic 1: Identify and develop new combination treatments using existing or innovative antimicrobials or antimicrobial with adjunctive treatments to extend drug efficacy and combat resistance. This topic focuses on overcoming resistance to antibiotics and antifungals in Human Health, Animal Health, and Plant Health. Proposals should develop combination therapies (antimicrobial combinations or antimicrobial with non-antimicrobial agents) to reduce resistance development and extend the usability of readily available antimicrobials. Studies must be based on scientific rationale and mechanisms of action. Improvement of existing combination treatments is also eligible, focusing on pharmacokinetics, pharmacodynamics, and administration modes. The choice of targeted pathogens must be justified, and for Human Health interests, the combination treatment should target bacterial or fungal pathogens from the WHO priority lists.

Topic 2: Develop tools and methods to improve adherence to treatment protocols. This topic addresses the issue of low adherence to treatment protocols by end-users (patients, farmers, citizens), which increases the risk of resistance. Proposals should identify reasons for poor adherence in Human, Animal, and Plant contexts, and/or develop innovative tools (including digital tools) and methods (including sociological and behavioural approaches) to improve adherence. Testing and comparing the efficiency of existing or innovative tools and methods is also encouraged. Engagement with end-users is mandatory, with consideration given to vulnerable groups with reduced access to healthcare services.

Topic 3: Assess the impact of antimicrobials for veterinary and agricultural use on the risk of AMR transmission to humans and the environment to inform policies on the restriction of some antimicrobials for human use. This topic aims to assess the impact of antibacterial and antifungal drugs used in veterinary and agricultural settings on the emergence and transmission of AMR to humans and the environment. Proposals should improve the formulation, dosage, delivery, routes of administration, and treatment regimens to decrease the risk of cross-resistance or transmission. The goal is to generate evidence for policies that restrict certain antimicrobials for exclusive human use and inform policies such as the WHO List of Medically Important Antimicrobials.

The submission process involves a two-step evaluation: pre-proposal and full proposal. Only transnational research and innovation projects are supported. Pre-proposals and full proposals must be in English and follow the provided templates. Submission is via the EUP OHAMR online platform. Some funding organizations may require additional submissions on their national/regional platforms. The project coordinator is the primary contact for communication with the EUP OHAMR Joint Call Secretariat (JCS).

The evaluation process includes a formal check by the JCS and national/regional funding organizations to ensure compliance with regulations. Proposals are evaluated by three reviewers based on Excellence, Impact, and Implementation criteria. A Peer Review Panel (PRP) meeting is held to discuss and agree on consensus scores. The board of funders decides which proposals are invited to submit a full proposal. Full proposals undergo a similar evaluation process, with ethics and legal requirements assessed at this stage. An Ethics Panel reviews proposals for compliance with ethical norms and regulations.

Applicants can appeal the evaluation outcome if they suspect a breach in the evaluation procedures. Appeals must be submitted within 7 calendar days of the notification of the evaluation outcome.

Evaluation criteria are based on three main aspects:

1. Excellence: Clarity and pertinence of objectives, credibility of approach and methodology, soundness and research base of the concept, novelty, potential to advance the field, and scientific excellence of the consortium.

2. Impact: Impact on achieving call objectives, potential for clinical, public health, animal health, agriculture, or environmental benefit, relevance to the One Health concept, potential for fostering international networks, potential reach of project results, and appropriateness of end-user and stakeholder participation.

3. Quality and efficiency of the implementation: Coherence and effectiveness of the work plan, adequate distribution of tasks, strength of transnational collaboration, integration of social, economic, equity, and cultural dimensions, quality of Open Science practices, data management, Intellectual Property management, appropriateness of management and governance structures, potential exploitation of findings, contingency plan, and justification of the budget.

Each criterion is scored from 0 to 5, with a threshold of 3 for individual criteria and 10 overall.

The EUP OHAMR is a 10-year programme launched in June 2025, involving 53 organizations from 30 countries. It aims to address AMR challenges through four programmes: R&I Funding, Capacity Strengthening, Data Exploitation, and Impact Programme. The R&I Funding programme focuses on preventing AMR emergence and spread, strengthening antimicrobial use and infection control, and providing innovative treatment options.

In summary, this call aims to fund transnational research and innovation projects that address critical aspects of antimicrobial resistance across human, animal, and environmental health. It seeks proposals that develop new treatments, improve adherence to existing treatments, and assess the impact of antimicrobial use in agriculture and veterinary medicine on the spread of AMR. The call follows a rigorous two-step evaluation process, emphasizing excellence, impact, and implementation quality, and requires strong transnational collaboration and adherence to ethical and legal standards. The ultimate goal is to generate evidence and tools to inform policies and practices that combat AMR and protect public health.

Eligible Applicant Types: The eligible applicant types are research and innovation funding organizations, key AMR actors, stakeholders, academia, industry including small and medium enterprises (SMEs). The program brings together 53 organizations from 30 countries in EU and beyond.

Funding Type: The primary financial mechanism is a grant, specifically through the R&I Funding programme which provides financial support to AMR R&I.

Consortium Requirement: A consortium of multiple applicants is required. The call supports transnational research and innovation projects.

Beneficiary Scope (Geographic Eligibility): The geographic eligibility includes EU countries and countries beyond the EU. The program involves 53 organizations from 30 countries in the EU and beyond.

Target Sector: The target sector is health, specifically focusing on antimicrobial resistance (AMR) across human health, animal health, plant health, food security, and the environment. It also includes agriculture.

Mentioned Countries: The opportunity mentions 30 countries in the EU and beyond.

Project Stage: The project stage includes research, innovation, development, and potentially demonstration, as the call aims to support projects that provide innovative and cost-effective treatment options and address various aspects of AMR related to therapeutics, diagnostics, surveillance, transmission, and evolution, as well as interventions.

Funding Amount: The total funding available is €31,000,000.00.

Application Type: The application type is an open call, specifically a Joint Transnational Call (JTC).

Nature of Support: Beneficiaries will receive money through the R&I Funding programme.

Application Stages: The application process involves two stages: submission of a pre-proposal, and if successful, an invitation to submit a full proposal.

Success Rates: The success rates are not explicitly mentioned, but the process involves a two-step evaluation, suggesting that the success rate is likely to be below 50% given the competitive nature of EU funding.

Co-funding Requirement: The document does not explicitly state whether co-funding is required. However, given that national/regional funding organizations are involved, it is possible that co-funding may be required at the national/regional level.

Summary:

The European Partnership on One Health AMR (EUP OHAMR) is launching a Joint Transnational Call (JTC) for research and innovation projects addressing antimicrobial resistance (AMR). This initiative is part of the Horizon Europe funding programme and aims to support projects that tackle AMR challenges across human health, animal health, plant health, food security, and the environment. The total funding available for this call is €31,000,000.00.

The call is structured around three main topics:
1. Identify and develop new combination treatments using existing or innovative antimicrobials or antimicrobial with adjunctive treatments to extend drug efficacy and combat resistance.
2. Develop tools and methods to improve adherence to treatment protocols.
3. Assess the impact of antimicrobials for veterinary and agricultural use on the risk of AMR transmission to humans and the environment to inform policies on the restriction of some antimicrobials for human use.

Eligible applicants include research and innovation funding organizations, key AMR actors, stakeholders, academia, industry (including SMEs), and other relevant entities from the EU and beyond. The application process is divided into two stages: a pre-proposal and a full proposal (for those successful in the first stage). Proposals must be submitted by a consortium of multiple applicants, emphasizing transnational collaboration.

The evaluation process includes a formal check by the Joint Call Secretariat (JCS) and national/regional funding organizations, followed by an independent evaluation by three reviewers. A Peer Review Panel (PRP) will then discuss the proposals and create ranking lists. Ethics and legal requirements will also be assessed, particularly at the full proposal stage. Applicants can appeal the evaluation outcome if they suspect a breach in the evaluation procedures.

The evaluation criteria are based on excellence, impact, and quality and efficiency of the implementation, each carrying equal weight. The call aims to fund projects that are relevant to the call topics, scientifically excellent, and have the potential to contribute to clinical, public health, animal health, agriculture, or environmental benefits.

In essence, this call is a significant opportunity for researchers and innovators to secure funding for projects that address the critical global challenge of antimicrobial resistance through collaborative, transnational efforts.